News

AstraZeneca facility at The Cove
AstraZeneca facility at the Cove in San Francisco (AstraZeneca)

        Britain-based Big Pharma AstraZeneca has penned a new collab with Belgium’s N-SIDE for its clinical studies.

       

        AZ will use N-SIDE’s cloud-based software for its tests, giving it "centralized management, real-time trial monitoring and results visualization," the firm said in a statement.

       

        The company told FierceCRO that: "The N-SIDE Suite for clinical trials supports strategic decision making throughout the clinical trial process, enabling clinical trial managers to future proof their supply chain management while also reducing cost, waste and risk."

Synthetic Controls: Best Practices and Regulatory Perspectives

With increasing competition for patients, the ability to effectively and efficiently execute on clinical development plans has increased focus on alternative data sources. In this one-hour session attendees will hear from former FDA leaders and industry experts who will address what Synthetic Control is and how it can be leveraged in clinical development.

        Specifically, AZ will use the N-SIDE “Supply and Dashboard Apps” to design, plan and monitor their clinical trial supply chain.

       

        John Murray, supply chain transformation lead at AstraZeneca, said: "N-SIDE’s Suite provides a tremendous opportunity for AstraZeneca to collaborate across key areas of clinical development and deliver the best studies for our patients."

       

        "We are proud to further our collaboration with AstraZeneca as they implement the N-SIDE Suite for Clinical Trials to manage their clinical supply chain," stated Jacques Parlongue, N-SIDE CEO.

       

        This new deal builds on the consulting services the firm has done for AstraZeneca’s clinical trial supply optimization since 2017.

       



Excerpt from URL:https://www.fiercebiotech.com/cro/astrazeneca-teams-up-n-side-for-trial-work



  ▲ Last article:   NICE nixes Roche's Tecentriq in tough-to-treat breast cancer ---Oct 2, 2019
  ▼ Next article:   Ex-Bioverativ CEO John Cox lands at Torque Therapeutics ---Oct 2, 2019
                    More ……      

 



News FullText Search